Randall Ellis Morris

Randall Ellis Morris's AcademicInfluence.com Rankings

Biology

#11453

World Rank

#14850

Historical Rank

Immunology

#734

World Rank

#756

Historical Rank

biology Degrees

Download Badge

Biology

Randall Ellis Morris's Degrees

Bachelors Biology Stanford University

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Randall Ellis Morris Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Randall Ellis Morris's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor (2003) (531)
Altered surfactant function and structure in SP-A gene targeted mice. (1996) (424)
The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. (1992) (419)
Comparison of the Effects of Tacrolimus and Cyclosporine on the Pharmacokinetics of Mycophenolic Acid (2001) (317)
Rapamycins: Antifungal, antitumor, antiproliferative, and immunosuppressive macrolides (1992) (260)
Newer immunosuppressive drugs: a review. (1999) (252)
Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. (1995) (231)
Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels. (1993) (222)
Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. (1990) (206)
Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. (1996) (189)
Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. (1999) (170)
Receptor-mediated internalization of pseudomonas toxin by mouse fibroblasts (1980) (163)
EFFECTS OF RAPAMYCIN ON GROWTH FACTOR‐STIMULATED VASCULAR SMOOTH MUSCLE CELL DNA SYNTHESIS INHIBITION OF BASIC FIBROBLAST GROWTH FACTOR AND PLATELET‐DERIVED GROWTH FACTOR ACTION AND ANTAGONISM OF RAPAMYCIN BY FK506 (1995) (161)
The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. (2008) (160)
Shigella Infection of Henle Intestinal Epithelial Cells: Role of the Host Cell (1979) (154)
Cell Cycle Protein Expression in Vascular Smooth Muscle Cells In Vitro and In Vivo Is Regulated Through Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin (2001) (148)
Identification of Heat Shock Protein 60 as the Ligand on Histoplasma capsulatum That Mediates Binding to CD18 Receptors on Human Macrophages1 (2003) (148)
Immunosuppressants: cellular and molecular mechanisms of action. (1996) (137)
Immunoregulatory role of transforming growth factor beta (TGF-beta) in development of killer cells: comparison of active and latent TGF-beta 1 (1990) (136)
Obliterative bronchiolitis after lung and heart-lung transplantation. (1995) (135)
Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease (1991) (135)
Therapeutic monitoring of mycophenolic acid. A consensus panel report. (1998) (132)
Stanford experience with obliterative bronchiolitis after lung and heart-lung transplantation. (1996) (126)
SIROLIMUS (RAPAMYCIN) HALTS AND REVERSES PROGRESSION OF ALLOGRAFT VASCULAR DISEASE IN NON-HUMAN PRIMATES1 (2000) (120)
Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. (2001) (120)
Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group (2019) (120)
Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. (1991) (112)
Mycophenolate Mofetil: A Report of the Consensus Panel (1995) (112)
Immunosuppression by the JAK3 Inhibitor CP-690,550 Delays Rejection and Significantly Prolongs Kidney Allograft Survival in Nonhuman Primates (2005) (109)
Regulation of the macrophage vacuolar ATPase and phagosome-lysosome fusion by Histoplasma capsulatum. (1999) (105)
Binding and uptake of pulmonary surfactant protein (SP-A) by pulmonary type II epithelial cells. (1989) (105)
Receptor-mediated entry of diphtheria toxin into monkey kidney (Vero) cells: electron microscopic evaluation (1985) (103)
The Transforming Growth Factor‐Betas: A New Family of Immunoregulatory Molecules (1990) (100)
Mechanisms of Action of New Immunosuppressive Drugs (1995) (100)
Differential effects of glucocorticoid on expression of surfactant proteins in a human lung adenocarcinoma cell line. (1988) (98)
Rapamycin: FK506's fraternal twin or distant cousin? (1991) (95)
Studies in experimental models of chronic rejection: use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis. (1995) (89)
Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions. (1991) (88)
Leflunomide and malononitrilamides. (1997) (88)
The role of respiratory epithelium in a rat model of obliterative airway disease. (2000) (83)
Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. (1999) (82)
Flow cytometric quantitation of calcium-dependent and -independent mitogen-stimulation of T cell functions in whole blood: inhibition by immunosuppressive drugs in vitro. (2001) (81)
Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. (1993) (79)
EPITHELIAL RE-GROWTH IS ASSOCIATED WITH INHIBITION OF OBLITERATIVE AIRWAY DISEASE IN ORTHOTOPIC TRACHEAL ALLOGRAFTS IN NON-IMMUNOSUPPRESSED RATS1 (2000) (72)
A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. (1990) (69)
Obliterative airway disease after heterotopic tracheal xenotransplantation: pathogenesis and prevention using new immunosuppressive agents. (1997) (69)
Pharmacodynamics of Mycophenolate Mofetil after Heart Transplantation: New Mechanisms of Action and Correlations with Histologic Severity of Graft Rejection (2002) (68)
A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2. (1996) (68)
Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides. (1995) (68)
Rapamycin inhibits development of obliterative airway disease in a murine heterotopic airway transplant model. (1997) (63)
Rapamycin (Sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells. (1995) (63)
Pharmacodynamics of immunosuppressive drugs. (2000) (63)
AnkB, a Periplasmic Ankyrin-Like Protein inPseudomonas aeruginosa, Is Required for Optimal Catalase B (KatB) Activity and Resistance to Hydrogen Peroxide (2000) (61)
Leflunomide (HWA 486) and its analog suppress T- and B-cell proliferation in vitro, acute rejection, ongoing rejection, and antidonor antibody synthesis in mouse, rat, and cynomolgus monkey transplant recipients as well as arterial intimal thickening after balloon catheter injury. (1995) (58)
Localization of ClC-2 Cl- channels in rabbit gastric mucosa. (2001) (58)
Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine. (2000) (57)
Anti‐non‐Gal porcine endothelial cell antibodies in acute humoral xenograft rejection of hDAF‐transgenic porcine hearts in cynomolgus monkeys (2004) (56)
Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. (1999) (55)
Quantification of Immunosuppression by Flow Cytometry in Stable Renal Transplant Recipients (2003) (55)
Normal surfactant pool sizes and inhibition-resistant surfactant from mice that overexpress surfactant protein A. (1999) (55)
Vascular endothelial growth factor in the rat pituitary: differential distribution and regulation by estrogen. (2000) (54)
Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability. (2000) (54)
Receptor-mediated entry of Pseudomonas toxin: methylamine blocks clustering step (1983) (54)
Coadministration of either cyclosporine or steroids with humanized monoclonal antibodies against CD80 and CD86 successfully prolong allograft survival after life supporting renal transplantation in cynomolgus monkeys. (2001) (54)
Potent and effective prolongation by anti-LFA-1 monoclonal antibody monotherapy of non-primarily vascularized heart allograft survival in mice without T cell depletion. (1993) (53)
The therapeutic prescription for the organ transplant recipient: the linkage of immunosuppression and antimicrobial strategies (1999) (53)
New small molecule immunosuppressants for transplantation: review of essential concepts. (1993) (53)
Weight gain after lung transplantation. (2003) (53)
Leflunomide and malononitriloamides. (1997) (53)
Mechanism of action for leflunomide in rheumatoid arthritis. (1999) (52)
Developing New Immunosuppression for the Next Generation of Transplant Recipients: The Path Forward (2016) (52)
Long-term survival of solid organ allografts by brief anti-lymphocyte function-associated antigen-1 monoclonal antibody monotherapy. (1996) (50)
Activation of human macrophage fungistatic activity against Histoplasma capsulatum upon adherence to type 1 collagen matrices. (1997) (50)
Effects of humanized monoclonal antibody to rhesus CD11a in rhesus monkey cardiac allograft recipients. (2000) (49)
Immunosuppressive therapies for the prevention and treatment of obliterative airway disease in heterotopic rat trachea allografts. (2000) (48)
Leflunomide effectively treats naturally occurring immune-mediated and inflammatory diseases of dogs that are unresponsive to conventional therapy. (1998) (48)
Clinical Trials for Immunosuppression in Transplantation: The Case for Reform and Change in Direction. (2017) (48)
Surfactant protein A-polylysine conjugates for delivery of DNA to airway cells in culture. (1995) (47)
Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo. (1997) (47)
Digestion of Histoplasma capsulatum yeasts by human macrophages. (1992) (47)
Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells (1997) (45)
Azurophilic granules of human neutrophils contain CD14 (1997) (45)
In vivo evaluation of the novel calcineurin inhibitor ISATX247 in non-human primates. (2003) (45)
Human Macrophages Do Not Require Phagosome Acidification to Mediate Fungistatic/Fungicidal Activity against Histoplasma capsulatum1 (2006) (45)
Enhanced Killing of Candida albicans by Human Macrophages Adherent to Type 1 Collagen Matrices via Induction of Phagolysosomal Fusion (2005) (45)
Evaluation of biomarker discovery approaches to detect protein biomarkers of acute renal allograft rejection. (2005) (44)
Cellular enzyme-linked immunospecific assay (CELISA). I. A new micromethod that detects antibodies to cell-surface antigens. (1982) (44)
Treatment with humanized monoclonal antibodies against CD80 and CD86 combined with sirolimus prolongs renal allograft survival in cynomolgus monkeys1 (2003) (44)
Feasibility of in vivo intravascular ultrasound tissue characterization in the detection of early vascular transplant rejection. (1999) (43)
PHARMACODYNAMICS OF MYCOPHENOLIC ACID IN HEART ALLOGRAFT RECIPIENTS: CORRELATION OF LYMPHOCYTE PROLIFERATION AND ACTIVATION WITH PHARMACOKINETICS AND GRAFT HISTOLOGY1 (2000) (41)
The novel calcineurin inhibitor ISA247: a more potent immunosuppressant than cyclosporine in vitro (2004) (41)
Prevention of neointimal proliferation by immunosuppression in synthetic vascular grafts. (2001) (41)
Human Dendritic Cell Activity against Histoplasma capsulatum Is Mediated via Phagolysosomal Fusion (2005) (41)
Graft-versus-host disease prevention by rapamycin: cellular mechanisms. (2000) (39)
Novel assays of multiple lymphocyte functions in whole blood measure: new mechanisms of action of mycophenolate mofetil in vivo. (2002) (38)
Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. (1999) (38)
Comparison of the immunosuppressive effects of mycophenolic acid and the morpholinoethyl ester of mycophenolic acid (RS-61443) in recipients of heart allografts. (1991) (38)
Immunosuppression with a combination of the leflunomide analog, FK778, and microemulsified cyclosporine for renal transplantation in mongrel dogs (2003) (37)
New immunosuppressive regimens in lung transplantation. (1997) (37)
THE IMMUNOPHARMACOLOGY OF IMMUNOSUPPRESSION BY 15‐DEOXYSPERGUALIN (1993) (37)
Mechanism of action of leflunomide: in vivo uridine administration reverses its inhibition of lymphocyte proliferation. (1996) (36)
Combination leflunomide and cyclosporine prevents rejection of functional whole limb allografts in the rat. (1997) (36)
Review of immunosuppression for lung transplantation. Novel drugs, new uses for conventional immunosuppressants, and alternative strategies. (1997) (35)
Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and (2000) (35)
Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720 (2010) (34)
Small airway obliteration in a new swine heterotopic lung and bronchial allograft model. (1998) (32)
Isolation and characterization of Pseudomonas aeruginosa exotoxin A binding glycoprotein from mouse LM cells. (1991) (32)
JAK3 inhibition as a new concept for immune suppression. (2003) (32)
Identification and characterization of Magmas, a novel mitochondria-associated protein involved in granulocyte-macrophage colony-stimulating factor signal transduction. (2001) (31)
Hepatic lobular patterns of phosphoenolpyruvate carboxykinase, glycogen synthase, and glycogen phosphorylase in fasted and fed rats. (1993) (30)
In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis. (1997) (30)
Up‐regulation of inducible nitric oxide synthase in fibroblasts parallels the onset and progression of fibrosis in an experimental model of post‐transplant obliterative airway disease (2000) (29)
Immunosuppression in cardiac transplantation: a new era in immunopharmacology (1995) (29)
Development of a high-performance liquid chromatographic-electrospray mass spectrometric assay for the specific and sensitive quantification of the novel immunosuppressive macrolide 40-O-(2-hydroxyethyl)rapamycin. (1998) (29)
Reduced temperature alters Pseudomonas exotoxin A entry into the mouse LM cell (1986) (29)
Single- and multiple-dose pharmacokinetics and pharmacodynamics of leflunomide's active metabolite A77 1726 in normal Lewis rats. (1996) (29)
High-performance liquid chromatographic assay with a simple extraction procedure for sensitive quantification of mycophenolic acid in rat and human plasma. (1999) (28)
Chronic rejection: The result of uncontrolled remodelling of graft tissue by recipient mesenchymal cells? Data from two rodent models and the effects of immunosupressive therapies (1999) (28)
The avidin-biotin system. (1984) (28)
Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine. (1995) (28)
RAD in stable lung and heart/lung transplant recipients: safety, tolerability, pharmacokinetics, and impact of cystic fibrosis. (2001) (28)
Pirfenidone: A novel anti-fibrotic agent and progressive chronic allograft rejection. (2002) (27)
Association of down-regulation of cytokine activity with rat hind limb allograft survival. (1995) (27)
Visualization of intracellular trafficking: use of biotinylated ligands in conjunction with avidin-gold colloids. (1984) (27)
Efficacies of sirolimus (rapamycin) and cyclosporine in allograft vascular disease in non-human primates: trough levels of sirolimus correlate with inhibition of progression of arterial intimal thickening (2000) (26)
Diphtheria toxin does not enter resistant cells by receptor-mediated endocytosis (1983) (26)
Combined immunosuppression with leflunomide and cyclosporine prevents MLR-mismatched renal allograft rejection in a mongrel canine model. (1996) (26)
The novel immunosuppressant SDZ‐RAD protects rat brain slices from cyclosporine‐induced reduction of high‐energy phosphates (2000) (25)
Immunosuppression in renal transplantation: some aspects for the modern era. (2008) (25)
Contribution of anti-Gal to primate and human IgG binding to porcine endothelial cells. (1995) (25)
The effect of soluble complement receptor type 1 on acute humoral xenograft rejection in hDAF‐transgenic pig‐to‐primate life‐supporting kidney xenografts (2005) (25)
Prevention and Treatment of Allograft Rejection in Vivo by Rapamycin: Molecular and Cellular Mechanisms of Action (1993) (25)
Sirolimus (Rapamycin) Monotherapy Prevents Graft Vascular Disease in Nonhuman Primate Recipients of Orthotopic Aortic Allografts (2003) (25)
Compared with Cyclosporine, ISATX247 Significantly Prolongs Renal-Allograft Survival in a Nonhuman Primate Model (2004) (25)
Evaluation of the in vivo dose-response relationship of immunosuppressive drugs using a mouse heart transplant model: application to cyclosporine. (1988) (24)
Immortalization of subpopulations of respiratory epithelial cells from transgenic mice bearing SV40 large T antigen. (1994) (24)
Obliterative airway disease after heterotopic tracheal xenotransplantation in a concordant rodent model: pathogenesis and treatment. (1996) (23)
Evidence for pseudomonas exotoxin A receptors on plasma membrane of toxin-sensitive lm fibroblasts (1984) (23)
Immunopharmacology of new xenobiotic immunosuppressive molecules. (1992) (23)
Enhancement of obliterative airway disease in rat tracheal allografts infected with recombinant rat cytomegalovirus. (1998) (23)
Leflunomide prolongs pulmonary allograft and xenograft survival. (1995) (23)
Treatment by Mycophenolate Mofetil of Advanced Graft Vascular Disease in Non‐Human Primate Recipients of Orthotopic Aortic Allografts (2003) (23)
Hyperacute rejection of hDAF‐transgenic pig organ xenografts in cynomolgus monkeys: influence of pre‐existing anti‐pig antibodies and prevention by the αGAL glycoconjugate GAS914 (2004) (22)
Progression of obliterative airway disease occurs despite the removal of immune reactivity by retransplantation. (1997) (22)
Co-administration of tacrolimus and mycophenolate mofetil does not increase mycophenolic acid (MPA) exposure, but co-administration of cyclosporine inhibits the enterohepatic recirculation of MPA, thereby decreasing its exposure. (2001) (22)
Effects of the malononitrilamide FK778 on immune functions in vitro in whole blood from non-human primates and healthy human volunteers. (2003) (22)
15-Deoxyspergualin is a more potent and effective immunosuppressant than cyclosporine but does not effectively suppress lymphoproliferation in vivo. (1991) (22)
Pirfenidone: a novel antifibrotic agent with implications for the treatment of obliterative bronchiolitis. (1998) (22)
In vitro evaluation of the effects of candidate immunosuppressive drugs: flow cytometry and quantitative real-time PCR as two independent and correlated read-outs. (2004) (21)
Sotrastaurin (AEB071) Alone and in Combination With Cyclosporine A Prolongs Survival Times of Non-Human Primate Recipients of Life-Supporting Kidney Allografts (2012) (21)
Level of receptor-associated protein moderates cellular susceptibility to pseudomonas exotoxin A (1995) (20)
Effects of leflunomide and cyclosporine on myocutaneous allograft survival in the rat. (1996) (20)
Rapamycin: A New and Highly Active Immunosuppressive Macrolide with an Efficacy Superior to Cyclosporine (1989) (19)
Successful treatment of acute, ongoing rat lung allograft rejection with the novel immunosuppressant SDZ-RAD. (2000) (19)
Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. (1990) (19)
Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation. (1991) (19)
Effect of splenectomy and mono- or combination therapy with rapamycin, the morpholinoethyl ester of mycophenolic acid and deoxyspergualin on cardiac xenograft survival. (1991) (19)
Inhibition of cellular protein synthesis by vaccinia virus surface tubules. (1982) (18)
Comparative effects of malononitriloamide analogs of leflunomide on whole blood lymphocyte stimulation in humans, rhesus macaques, cats, dogs, and rats. (1998) (18)
Immunopharmacology of FK-506. (1989) (18)
A life-supporting technique of renal allotransplantation in Macaca fascicularis to evaluate novel immunosuppressive drugs in nonhuman primates. (2002) (18)
The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium's position statement (2019) (17)
Comparison of the immunosuppressive and toxic effects of FK506 and cyclosporine in xenograft recipients. (1989) (17)
Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay (1999) (17)
Treatment with rapamycin blocks arterial intimal thickening following mechanical and alloimmune injury. (1993) (17)
VIRAL SERINE PROTEINASE INHIBITOR (SERP-1) EFFECTIVELY DECREASES THE INCIDENCE OF GRAFT VASCULOPATHY IN HETEROTOPIC HEART ALLOGRAFTS1 (2001) (17)
Sustained suppression of peripheral blood immune functions by treatment with mycophenolate mofetil correlates with reduced severity of cardiac allograft rejection. (2004) (17)
Visualization of intracellular trafficking of proteins. (1990) (16)
Preliminary in vivo pharmacokinetic and pharmacodynamic evaluation of a novel calcineurin-independent inhibitor of NFAT (2004) (16)
T cell subsets required for protection against age-dependent polioencephalomyelitis of C58 mice. (1982) (16)
Anti‐pig antibody levels in non‐human primates of various origin (2004) (16)
Age-related loss of Lyt-1,2 cells in C58 mice results in susceptibility to lactic dehydrogenase virus-induced polioencephalomyelitis (1983) (16)
In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use. (1991) (15)
SP100030 is a novel T-cell-specific transcription factor inhibitor that possesses immunosuppressive activity in vivo. (1996) (15)
The antiproliferative effect of leflunomide on vascular smooth muscle cells in vitro is mediated by selective inhibition of pyrimidine biosynthesis. (1996) (15)
How Does Leflunomide Modulate the Immune Response in Rheumatoid Arthritis? (1999) (15)
Pharmacodynamics in the Development of New Immunosuppressive Drugs (2004) (15)
In vivo pharmacokinetic and pharmacodynamic evaluation of the malononitrilamide FK778 in non-human primates (2003) (14)
Bronchial epithelial cell-derived cytokine IL-10 and lung fibroblast proliferation. (2001) (14)
Essential role of calcium in cellular internalization of Pseudomonas toxin (1982) (14)
Prolongation of rat cardiac allograft survival by splenectomy following transplantation. (1974) (14)
An evaluation of combined immunosuppression with MNA 715 and microemulsified cyclosporine on renal allograft rejection in mismatched mongrel dogs. (2002) (14)
Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine. (1995) (13)
Airway Goblet Cells and Respiratory Epithelial Injury in an Animal Model of Obliterative Airways Disease (OAD) (2001) (13)
VIRAL SERINE PROTEINASE INHIBITOR (SERP‐1) EFFECTIVELY DECREASES THE INCIDENCE OF GRAFT VASCULOPATHY IN HETEROTOPIC HEART ALLOGRAFTS.: Abstract# 895 Poster Board #‐Session: P152‐III (2000) (13)
Therapeutic monitoring of mycophenolic acid (MPA): Assays of immune function in peripheral blood predict efficacy for inhibition of histologic graft rejection (1999) (13)
Cellular enzyme-linked immunospecific assay (CELISA). IV. Inhibition of endogenous cellular alkaline phosphatase activity. (1984) (13)
Strongly reduced alloreactivity and long‐term survival times of cardiac allografts in Vav1‐ and Vav1/Vav2‐knockout mice (2007) (13)
Effects of the new and highly active immunosuppressant, rapamycin, on lymphoid tissues and cells in vivo. (1991) (13)
Evaluation of the clinical and histologic features of renal allograft rejection in cats. (2002) (13)
Validation of the biotinyl ligand-avidin-gold technique. (1992) (13)
Triple drug treatment with cyclosporine, leflunomide and mycophenolate mofetil prevents rejection of pig islets transplanted into rats and primates. (1997) (12)
NOVEL MECHANISMS OF ACTION OF MYCOPHENOLIC ACID (MPA): INHIBITION OF EXPRESSION OF CD28 AND CD154 CO‐STIMULATORY MOLECULES AND INDUCTION OF APOPTOSIS IN VIVO IN HUMANS AFTER TREATMENT WITH MYCOPHENOLATE MOFETIL (MMF).: Abstract# 1078 (2000) (12)
Improved assessment of graft function by echocardiography in cynomolgus monkey recipients of hDAF-transgenic pig cardiac xenografts. (2005) (12)
Leflunomide analog, MNA-715, plus cyclosporine reduces renal allograft rejection in mismatched dogs. (2001) (12)
Mouse liver contains a Pseudomonas aeruginosa exotoxin A-binding protein (1991) (12)
PHARMACODYNAMICS OF CYCLOSPORINE‐KETOCONAZOLE INTERACTION IN MICE: COMBINED THERAPY POTENTIATES CYCLOSPORINE IMMUNOSUPPRESSION AND TOXICITY (1987) (12)
Use of biomarkers to improve immunosuppressive drug development and outcomes in renal organ transplantation: A meeting report (2020) (12)
ATP-binding cassette transporters and calcineurin inhibitors: potential clinical implications. (2001) (11)
Vascular and cellular mechanisms of chronic renal allograft dysfunction. (2001) (11)
Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay. (1998) (11)
Assessment of cardiac rejection and immunosuppression by magnetic resonance imaging and spectroscopy. (1995) (11)
Intracellular trafficking of Pseudomonas exotoxin A. (1987) (11)
Cellular enzyme-linked immunospecific assay (CELISA). III. Use of the CELISA to quantitate monoclonal antibodies bound to HLA antigens and to subset-specific antigens on cell surfaces. (1983) (11)
Effect of anesthesia on a whole blood lymphocyte proliferation assay in the rat. (1999) (11)
Immunosuppressive effects of surgery assessed by flow cytometry in nonhuman primates after nephrectomy (2005) (11)
A novel inhibitor of nuclear factor-kappa B and activator protein-1 transcription factors in T cells suppresses host-versus-graft alloreactivity in vivo. (1997) (10)
Infiltrating recipient mesenchymal cells form the obliterative airway disease lesion and dramatically remodel graft tissue in a model of chronic lung rejection. (1997) (10)
PROLONGED INHIBITION OF OBLITERATIVE AIRWAY DISEASE IN MURINE TRACHEAL ALLOGRAFTS BY BRIEF TREATMENT WITH ANTI-LEUKOCYTE FUNCTION-ASSOCIATED ANTIGEN-1 (CD11a) MONOCLONAL ANTIBODY1 (2001) (10)
Modified Noble Plication for the Prevention of Intestinal Intussusception After Renal Transplantation in Dogs (2003) (9)
A non-lymphocyte-depleting monoclonal antibody to the adhesion molecule LFA-1 (CD11a) prevents sensitization to alloantigens and effectively prolongs the survival of heart allografts. (1993) (9)
The xenoantibody response and immunoglobulin gene expression profile of cynomolgus monkeys transplanted with hDAF‐transgenic porcine hearts (2007) (9)
Theoretical benefits of mitogen applications for HIV-1 infections. (1997) (9)
Multidimensional assessment of graft vascular disease (GVD) in aortic grafts by serial intravascular ultrasound in rhesus monkeys. (2000) (9)
New mechanisms of action of mycophenolate mofetil in transplant recipients by assessment of its pharmacodynamics. (2001) (9)
Expression of virion and tumor-specific antigens on the surface of chick embryo cells infected with strain MC29 avian leukosis virus. (1976) (9)
Endocardial mononuclear cell infiltrates (Quilty effect) in heterotopic cardiac allografts in rapamycin-treated rats. (1994) (9)
Potentiation of immunosuppressive efficacy by combining the novel leflunomide analog, HMR 279, with microemulsion cyclosporine in a rat lung transplant model. (1999) (8)
EFFECTS OF AGI-1096, A NOVEL ANTIOXIDANT COMPOUND WITH ANTI-INFLAMMATORY AND ANTIPROLIFERATIVE PROPERTIES, ON RODENT ALLOGRAFT ARTERIOSCLEROSIS (2004) (8)
Assessment of mechanisms of action of immunosuppressive drugs using novel whole blood assays. (2001) (8)
Gold enhancement of gold-labeled probes: gold-intensified staining technique (GIST). (1991) (8)
The histology of subcutaneously implanted donor bronchial rings correlates with rejection scores of lung allografts in a primate lung transplant model. (1999) (8)
Initial experience with FK 506 as an immunosuppressant for nonhuman primate recipients of cardiac allografts. (1991) (8)
Efficacy of didemnin B in suppressing allograft rejection in mice and rats. (1989) (8)
The importance of the spleen for the immunosuppressive action of cyclosporine in transplantation. (1991) (8)
Donor treatment with the lazeroid U74389G reduces ischemia-reperfusion injury in a rat lung transplant model. (1997) (8)
Ultrastructural visualization of virus-induced surface antigens. Comparative studies of three immunohistochemical techniques. (1975) (7)
Histological and immunological characteristics of, and the effect of immunosuppressive treatment on, xenograft vasculopathy (2004) (7)
Inhibition of the activity of pseudomonas toxin by methylamine. (1983) (7)
New World monkeys as a primate model for xenografts in the absence of anti-Gal. (1996) (7)
Hyperacute rejection of orthotopic cardiac allografts in dogs following solubilized antigen pretreatment. (1973) (7)
Combined use of immunoferritin and immunocolloidal gold for the simultaneous demonstration of two antigens by immuno-electron microscopy. (1982) (7)
Brief treatment with rapamycin in vivo increases responsiveness to alloantigens measured by the mixed lymphocyte response. (1992) (7)
Immunoregulatory Role of Transforming Growth Factor 0 ( TGF-0 ) in Development of Killer Cells : Comparison of Active and Latent TGF-01 By (2003) (7)
Brequinar sodium (Dup 785) is a highly potent antimetabolite immunosuppressant that suppresses heart allograft rejection (1991) (7)
Religious obstacles and warrants for the donation of body parts. (1988) (7)
Mycophenolate in the prevention of recurrent neutralizing botulinum toxin A antibodies in cervical dystonia (2000) (6)
A new large-animal model for research of graft vascular disease. (1998) (6)
Tacrolimus for prevention of liver allograft rejection: clinical trials and tribulations (1995) (6)
Immunologic monitoring of cardiac transplant recipients by a modified reactive leukocyte blastogenesis assay (MRLB). (1978) (6)
Enhanced nitric oxide production induced by the administration of L-arginine does not inhibit arterial neointimal formation after overwhelming alloimmune injury. (1996) (6)
Use of echocardiography to assess function of hDAF-transgenic pig cardiac xenografts. (2005) (5)
A new large animal heterotopic lung and bronchial allograft model for research in obliterative bronchiolitis. (1997) (5)
Sustained food vacuole formation by axenic Paramecium tetraurelia and the inhibition of membrane recycling by Alcian Blue. (1992) (5)
Alterations in inducible nitric oxide synthase (iNOS) and nitrotyrosine (NitroY) during re-epithelialization of heterotopic rat tracheal composite grafts. (1999) (5)
Cyclophosphamide-induced postoperative anemia in cynomolgus monkey recipients of hDAF-transgenic pig organ xenografts. (2002) (5)
New approach in drug development: whole blood pharmacodynamic assays reflect biological activities of tacrolimus. (2001) (5)
Failure to demonstrate a role for line Ib tumor-associated surface antigen in the etiology of age-dependent polioencephalomyelitis. (1982) (5)
Development of models of graft vascular disease in nonhuman primates: evaluation of GVD by intravascular ultrasound in a new cynomolgus model with arterial allograft exchange. (1999) (5)
COADMINISTRATION OF TACROLIMUS AND MYCOPHENOLATE MOFETIL DOES NOT INCREASE MYCOPHENOLIC ACID (MPA) EXPOSURE, BUT COADMINISTRATION OF CYCLOSPORINE INHIBITS THE ENTEROHEPATIC RECIRCULATION OF MPA, THEREBY DECREASING ITS EXPOSURE.: Abstract# 301 Poster Board #‐Session: P148‐I (2000) (5)
In vivo evaluation of the effects of altered cyclosporine metabolism on its immunosuppressive potency. (1989) (5)
Immunosuppressive drugs after lung transplantation (1998) (4)
Quantitation of tumor antigen expression on the surface of malignant line Ib lymphocytes by immuno-electron microscopy. (1981) (4)
Hamster cardiac xenografts are protected against antibody mediated damage, early after transplantation to Lewis rats (2001) (4)
VX-497 inhibits IMPDH and is the first rationally synthesized immunosuppressant to prolong allograft survival (1999) (4)
Mechanisms of action of new immunosuppressive drugs. (1995) (4)
Prevention of cardiac allograft rejection by FK506 and rapamycin: assessment by histology and nuclear magnetic resonance. (1992) (4)
Mycophenolate mofetil pharmacodynamics and pharmacokinetics correlate with rejection score in a BN-to-LEW heterotopic heart transplant model. (2001) (4)
Respiratory epithelial expression of integrin αvβ6 in chronic progressive allograft rejection (2004) (4)
Tumor and histocompatibility antigen interaction: direct visualization by a double-label bridging technique for immuno-electron microscopy. (1982) (4)
Uptake and processing of toxins by mammalian cells. (1994) (4)
Beware: shifting paradigms ahead (1996) (4)
Lectin activity of the major surfactant protein (SP-A) may participate in, but is not required for, binding to rat type II cells. (1992) (4)
Pharmacologic Immunosuppressants in Xenotransplantation (1997) (4)
Route of pseudomonas and diphtheria toxin entry into mammalian cells: basis for susceptibility to toxin. (1985) (4)
A simple reliable method for producing electron dense markers of uniform size for use in immunoelectron microscopy. (1982) (4)
Visualization of Intracellular Trafficking (1984) (3)
Optimal visualization of immunogold-silver staining of hepatic PEPCK with epipolarized light microscopy. (1994) (3)
Intravenously injected anti-cardiac myosin monoclonal antibody specifically demarcates cardiac rejection. (1987) (3)
Assessment of new immunosuppressive drugs in a rat cardiac allograft heterotopic model. (1992) (3)
Effect of immunosuppression on obliterative lesions in a heterotopic large-animal bronchial allograft model. (1997) (3)
INHIBITION OF DIHYDROOROTATE DEHYDROGENASE (DHODH) IS THE MOLECULAR MECHANISM OF IMMUNOSUPPRESSION BY THE MALONONITRILAMIDES (MNAs) IN VIVO (1998) (3)
Respiratory epithelial expression of integrin alphaVbeta6 in chronic progressive allograft rejection. (2004) (3)
PHARMACODYNAMICS (PD) OF MYCOPHENOLATE MOFETIL (MMF) AFTER HEART TRANSPLANTION IDENTIFY NEW MECHANISM OF ACTION AND CORRELATE WITH SEVERITY OF REJECTION (1999) (3)
The immunologic diagnosis of orthotopic cardiac allograft rejection in dogs. (1973) (3)
The future of immunosuppression: a personal view. (2004) (3)
Graft thrombosis in hDA-transgenic pig hearts transplanted into rhesus monkeys. (2003) (3)
In vivo effect of sirolimus on T cells, B cells and monocytes in non-human primates. (2001) (2)
Quilty effect in heterotopic cardiac allografts in malononitrilamide-treated rats. (1999) (2)
DEVELOPMENT OF A NOVEL PHARMACODYNAMIC ASSAY IN NON‐HUMAN PRIMATES.: Abstract# 52 (2000) (2)
Sirolimus (Rapamycin) monotherapy prevents graft vascular disease in non-human primates (2002) (2)
Epipolarization microscopic immunogold assay: a combination of immunogold silver staining, enzyme-linked-immunosorbent assay and epipolarization microscopy. (1995) (2)
Letter: Clarification of certain characteristics of chicken antilymphocyte globulin. (1976) (2)
Trafficking ofPseudomonas exotoxin a in mammalian cells (1985) (2)
GRAFT REJECTION IN MYCOPHENOLIC ACID (MPA) TREATED HEART TRANSPLANT RECIPIENTS IS PREDICTED BY CHANGES IN LYMPHOCYTE FUNCTION OVER TIME (PHARMACODYNAMICS) (1999) (2)
Donor pretreatment with ambroxol or dexamethasone fails to ameliorate reperfusion injury in experimental lung transplantation (1998) (2)
IMMUNOSUPPRESSION WITH THE NEW LEFLUNOMIDE (LFM) ANALOG, HMR1715 PLUS CYCLOSPORINE (CsA) REDUCES CLINICAL AND HISTOLOGIC EVIDENCE OF RENAL ALLOGRAFT REJECTION IN MLR MISMATCHED DOGS.: Abstract# 294 Poster Board #‐Session: P141‐I (2000) (2)
A comparison of the in vitro and in vivo immunologic activities of concanavalin A and its succinylated derivative. (1987) (2)
The IMPDH inhibitor VX-497 is the first rationally synthesized immunosuppressant to prolong allograft survival (1999) (2)
COADMINISTRATION OF MICROEMULSION CYCLOSPORINE AND THE NOVEL LEFLUNOMIDE MALONONITRILAMIDE ANALOG, HR1279, MORE EFFECTIVELY SUPPRESSES RAT LUNG ALLOGRAFT REJECTION THAN MICROEMULSION CYCLOSPORINE PLUS LEFLUNOMIDE (1998) (2)
Squirrel monkeys hyperacutely reject porcine musculocutaneous flaps despite a lack of naturally occurring xenoantibodies. (1998) (2)
Enhancement of antigenic site detection with gold labeled secondary and tertiary antibodies using the immunogold-silver staining method. (1993) (2)
Monitoring Of Pharmacodynamics (pd), But Not Pharmacokinetics (pk), Differentiates The Relative Immunosuppressive Potencies Of Leflunomide And Its Malononitrilamide (mna) Analogs (1998) (2)
Commentary on new xenobiotic immunosuppressants for transplantation: Where are we, how did we get here, and where are we going? (1993) (2)
Ketoconazole potentiates cyclosporine immunosuppression and toxicity in mice. (1987) (2)
New Agents on the Horizon (2001) (2)
RECIPIENT MESENCHYMAL CELLS INFILTRATE AND REMODEL MEDIAL AND ADVENTITIAL TISSUE IN THE RAT FEMORAL ARTERY ALLOGRAFT MODEL OF CHRONIC VASCULAR REJECTION (1998) (2)
COADMINISTERED NEORAL AND THE NEW RAPAMYCIN DERIVATIVE, SDZ RAD, FOR NONHUMAN PRIMATE LUNG TRANSPLANTATION: SYSTEMATIC PHARMCOKINETIC-BASED TRIALS TO MAXIMIZE EFFICACY AND TOLERABILITY (1998) (2)
Chronic Rejection in Non-human Primates: Sirolimus (Rapamycin), but not Cyclosporin, Prevents Graft Vascular Disease (GVD) in Aortic Allografts after Acute Rejection. (1999) (2)
Effect of a novel anti-oxidant and anti-inflammatory compound on rodent allograft arteriosclerosis (2002) (1)
Alteration of in vivo allogeneic functions by ultraviolet B. (1989) (1)
Immunogold-silver staining and epipolarized light microscopic detection of phosphoenolpyruvate carboxykinase and glycogen phosphorylase in rat liver (1993) (1)
CHICKEN ANTI‐RAT LYMPHOCYTE GLOBULIN: DOSE RESPONSE STUDY AND DETERMINATION OF STRAIN‐SPECIFIC ALLO ANTIBODY (1979) (1)
Chicken antilymphocyte globulin: a source of heterologous enhancing antibody. (1977) (1)
Hepatic Subcellular Compartmentation of Cytoplasmic Phosphoenolpyruvate Carboxykinase Determined by Immunogold Electron Microscopy (1995) (1)
Assessing kidney function in transplant recipients: time to work together and address the most relevant questions. (2014) (1)
Drug Evaluation Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis Leflunomide and malononitriloamides (1997) (1)
Loss of airway goblet cells is associated with respiratory epithelial injury in a rat model of allograft rejection (1999) (1)
Preliminary in vivo pharmacokinetic and pharmacodynamic evaluation of a novel calcineurin‐independent inhibitor of NFAT (2004) (1)
PREVENTION OF OBLITERATIVE BRONCHIOLITIS BY JAK 3 INHIBITION WITH CP-690,550 IS ACCOMPANIED BY A DISTINCT GROWTH FACTOR GENE EXPRESSION PROFILE. (2004) (1)
Xenogeneic antibodies are not necessary for chronic rejection of vascularised xenografts (1999) (1)
Strategies in the prevention of chronic rejection (1998) (1)
Epithelial re-growth prevents luminal occlusion in orthotopic tracheal allografts despite acute rejection and proliferation of α-actin positive cells (1999) (1)
Immunosuppressive Drugs in Solid Organ Transplantation (2016) (0)
New immunosuppressive strategies in renal transplantation: new answers to old questions (1996) (0)
Use of rapamycin for the preparation of a medicament for the prevention and treatment of hyperproliferative vascular diseases, optionally in combination with mycophenolic acid (1995) (0)
Inhibition of throm☐ane A2 and platelet adhesion with salicylic acid effectively ameliorates reperfusion injury following acute double lung transplantation in the rat (1999) (0)
In vivo pharmacokinetic and pharmacodynamic evaluation of the malononitrilamide FK778 in non‐human primates (2003) (0)
IL-6 and IFN-γ expression parallels recovery of the epithelium in a heterotopic rat model of allograft rejection (1999) (0)
Experimental Immunosuppressive Agents (2001) (0)
This information is current as Human Macrophages Mediates Binding to CD 18 Receptors on That Histoplasma capsulatum Ligand on Identification of Heat Shock Protein 60 as the (2002) (0)
New immunosuppressive compounds in transplantation (1992) (0)
PHARMACODYNAMIC ASSAYS FOR THE IMMUNOSUPPRESSIVE EFFECT OF MPA: DIFFERENT WHOLE BLOOD LYMPHOCYTE FUNCTION ASSAYS AND THEIR CORRELATION WITH GRAFT HISTOLOGY (1999) (0)
TISSUE DISTRIBUTION OF THE NOVEL MACROLIDE IMMUNOSUPPRESSANT SDZ-RAD: INTERACTION WITH CYCLOSPORINE (1999) (0)
Pharmaceutical composition for treating hyperproliferative vascular disease (1995) (0)
A new, rapid, high-capacity chromatographic purification of IgG 1 monoclonal antibodies directly from mouse ascites fluid. (1987) (0)
An Examination of the Structure and Functions of the Bovine Vacuolar ATPase Using Antisense Oligonucleotides (1993) (0)
More pitfalls in the use of monoclonal antibodies (2004) (0)
Prevention of Arterial Restenosis by Rapamycin and Mycophenolate Mofetil: A New Role for Novel Immunosuppressants in the Prevention of Post-Balloon Angioplasty Restenosis? (1997) (0)
195 MOLECULAR MECHANISM OF THE IMMUNOSUPPRESSIVE EFFECT OF LEFLUNOMIDE IN VIVO: INHIBITION OF DIHYDROOROTATE DEHYDROGENASE (DHODH). (1997) (0)
Randall E. Morris, MD, FRCP: Stanford University School of Medicine and former Global Head of Transplantation Therapeutic Area (Discovery Research) and Global Head of Transplantation Translational Medicine, Novartis, AG, Basel, Switzerland. (2015) (0)
Efficacies of sirolimus (rapamycin) and cyclosporine in allograft vascular disease in non‐human primates: trough levels of sirolimus correlate with inhibition of progression of arterial intimal thickening (2000) (0)
Letter to the Editor (2003) (0)
A novel approach to test immunosuppressive drugs in heterotopically transplanted lung fragments in rats (1999) (0)
Use of rapamycin for the manufacture of a medicament for the bow and treatment of hyperproliferative Gefässerkrankheiten, possibly in combination with mycophenolic acid (1995) (0)
Sources of noncomplement-binding xenoantibody for passive enhancement of allografts. (1982) (0)
Discovery and development of immunosuppressants for transplantation: what are the lessons for specialty medicines? (2008) (0)
SAFETY AND TOLERABILITY OF TWO DIFFERENT SINGLE DOSES OF SDZ RAD IN LUNG TRANSPLANT RECIPIENTS. (1998) (0)
Impaired vascular distensibility prior to intimal proliferation in transplant vasculopathy (1998) (0)
LONGTERM CARDIAC ALLOGRAFT SURVIVAL IN VAV1 KNOCKOUT MICE (2004) (0)
Modulation of t cell function related to pathogenesis of immune polioencephalomyelitis (ipe) in c58 mice. Abstr. (1979) (0)
194 SINGLE- AND MULTIPLE-DOSE PHARMACOKINETICS (PK) OF TWO LEFLUNOMIDE ANALOGUES, THE MALONONITRILAMIDES (MNAS) HMR1279 AND HMR1715 (1996) (0)
microscopy. Optimal visualization of immunogold-silver staining of hepatic PEPCK with epipolarized light (2011) (0)
196 RELEVANCE OF COMBINED PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) STUDIES TO OPTIMIZE ADMINISTRATION AND EFFICACY OF TWO LEFLUNOMIDE ANALOGUES, THE MALONONITRILAMIDES (MNAS) HMR1279 AND HMR1715. (1997) (0)
Advances in Transplantation: Editorial. (2015) (0)
Brequinar sodium effectively and potently suppresses allograft rejection in a heterotopic mouse heart transplant model. (1993) (0)
POTENCIES OF IMMUNOSUPPRESSIVE DRUGS FOR INHIBITION OF SIGNAL 1- AND SIGNAL 2-INDUCED EXPRESSION OF LYMPHOCYTE CELL SURFACE ACTIVATION ANTIGENS USING WHOLE BLOOD ASSAYS (1999) (0)
Concanavalin A (CA) and its succinylated derivative (SCA) are nontoxic immunosuppressants of graft rejection (1986) (0)
Prevention of Obliterative Airway Disease (OAD) without Immunosuppression in Heterotopic Rat Tracheal Allografts: Anastomosis of Recipient Trachea to Donor Trachea Enables Re-epithelialization of Allografts by Recipient Epithelium (1998) (0)
SDZ‐RAD PREVENTS CYCLOSPORINE‐INDUCED INHIBITION OF BRAIN ENERGY METABOLISM: COMPARISON WITH RAPAMYCIN.: Abstract# 314 Poster Board #‐Session: P161‐I (2000) (0)
SOTRASTAURIN, (AEB071), PROLONGS KIDNEY ALLOGRAFT SURVIVAL ALONE OR IN COMBINATION WITH CYCLOSPORINE IN NON-HUMAN PRIMATES (2012) (0)
GRAFT VASCULAR DISEASE (GVD) IN NON HUMAN PRIMATES: QUANTITATION OF CHANGES IN ARTERIAL AUTO- AND ALLOGRAFTS BY INTRAVASCULAR ULTRASOUND (IVUS) (1998) (0)
COADMINISTRATION OF EITHER MICROEMULSION CYCLOSPORINE OR STEROIDS WITH HUMANIZED MONOCLONAL ANTIBODIES AGAINST THE B7‐1 AND B7‐2 EPITOPES SUCCESSFULLY PROLONG ALLOGRAFT SURVIVAL AFTER LIFE SUPPORTING RENAL TRANSPLANTATION IN CYNOMOLGUS MONKEYS.: Abstract# 47 (2000) (0)
The pharmaceutical composition for preventing hyperproliferative vascular disease (1995) (0)
immunosuppressant SDZ-RAD Successful treatment of acute, ongoing rat lung allograft rejection with the novel (2013) (0)
Prolongation of rat renal allograft survival by chicken antirat lymphocyte globulin. (1973) (0)
A method for the treatment of hyperproliferative diseases, using rapamycin, optionally in the comb. with mycophenolic (1993) (0)
Lobular and cellular distribution and content of glycogen synthase in periportal and pericentral hepatocytes of the rat liver (1993) (0)
Basiliximab (αIL2R Mab) induction therapy combined with subtherapeutic doses of neoral and SDZ RAD successfully prevents allograft rejection in a nonhuman primate lung transplant model (1999) (0)
Susceptibility of Mammalian Cells to Pseudomonas Exotoxin A (1993) (0)
SAFETY AND PHARMACOKINETICS OF TWO SINGLE DOSES OF RAD001 (RAD) IN STABLE LUNG AND HEART/LUNG TRANSPLANT RECIPIENTS WITH AND WITHOUT CYSTIC FIBROSIS (CF).: Abstract# 115 (2000) (0)
Tissue Distribution and Clinical Monitoring of the Novel Macrolide Immunosuppressant SDZ-RAD and Its Metabolites in Monkey Lung Transplant Recipients : Interaction with Cyclosporine 1 (2000) (0)
Treatment of hyperproliferative diseases (1995) (0)
Splenectomy antagonizes the action of cyclosporine. (1988) (0)
Induction of immune polioencephalomyelitis in c58 mice by solubilized line ib antigen. Abstr. (1976) (0)
Prevention of cardiac allograft rejection by FK506 and rapamycin: assessment by histology and nuclear magnetic resonance (1992) (0)
COMPARISON OF IN VITRO AND EX VIVO PHARMACODYNAMIC (PD) ASSAYS OF T CELL IMMUNOSUPPRESSANTS IN LEWIS RATS AND CYNOMOLGUS MONKEYS (2004) (0)
Composition for treatment of hypervascularization disease (1993) (0)
Coadministration of neoral and the novel rapamycin analog, sdzrad,to. lung allograft recipients:potentiation of immunosuppressive efficacy and reduction of toxicity by staggered vs. simultaneous treatment (1998) (0)
Transplantation. Beware: shifting paradigms ahead. (1996) (0)
FIRST PHARMACOKINETIC STUDY WITH SDZ RAD IN STABLE LUNG TRANSPLANT RECIPIENTS (1998) (0)
CD28 COSTIMULATION OF PROLIFERATION IN MURINE SPLENIC T CELLS IS SENSITIVE TO INHIBITION BY SP100030, A NOVEL T CELL-SPECIFIC DUAL INHIBITOR OF NF-κB AND AP-1 (1998) (0)
COMPARATIVE STUDIES OF THREE IMMUNOHISTOCHEMICAL TECHNIQUES (1975) (0)
Methode de prevention de vasculopathies hyperproliferatives (1995) (0)
LUNG EPITHELIUM-DERIVED IL-10 STIMULATES LUNG FIBROBLAST PROLIFERATION IN VITRO: IMPLICATIONS FOR THE PATHOGENESIS OF OBLITERATIVE BRONCHIOLITIS AFTER LUNG TRANSPLANTATION (1998) (0)
A method for the treatment of vascular disease hyperproliferaktiven using rapamycin in combination with mycophenolic acid may (1993) (0)
Internalization of pseudomonas exotoxin a utilizes the α macroglobulin receptor/low density lipoprotein receptor related protein (1995) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Randall Ellis Morris?

Randall Ellis Morris is affiliated with the following schools:

Randall Ellis Morris's Academic­Influence.com Rankings